299 related articles for article (PubMed ID: 32492831)
1. The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia.
Muñoz M; Coveñas R
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32492831
[TBL] [Abstract][Full Text] [Related]
2. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
Coveñas R; Rodríguez FD; Robinson P; Muñoz M
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958914
[TBL] [Abstract][Full Text] [Related]
3. Aprepitant Sensitizes Acute Myeloid Leukemia Cells to the Cytotoxic Effects of Cytosine Arabinoside in vitro and in vivo.
Wu H; Cheng X; Huang F; Shao G; Meng Y; Wang L; Wang T; Jia X; Yang T; Wang X; Fu C
Drug Des Devel Ther; 2020; 14():2413-2422. PubMed ID: 32606608
[TBL] [Abstract][Full Text] [Related]
4. The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?
Muñoz M; Coveñas R
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32962202
[TBL] [Abstract][Full Text] [Related]
5. Neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload.
Ge C; Huang H; Huang F; Yang T; Zhang T; Wu H; Zhou H; Chen Q; Shi Y; Sun Y; Liu L; Wang X; Pearson RB; Cao Y; Kang J; Fu C
Proc Natl Acad Sci U S A; 2019 Sep; 116(39):19635-19645. PubMed ID: 31488714
[TBL] [Abstract][Full Text] [Related]
6. Antagonism of NK-1R using aprepitant suppresses inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes.
Liu X; Zhu Y; Zheng W; Qian T; Wang H; Hou X
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1628-1634. PubMed ID: 31010320
[TBL] [Abstract][Full Text] [Related]
7. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists.
Muñoz M; González-Ortega A; Rosso M; Robles-Frias MJ; Carranza A; Salinas-Martín MV; Coveñas R
Peptides; 2012 Dec; 38(2):318-25. PubMed ID: 23026680
[TBL] [Abstract][Full Text] [Related]
8. Combination Therapy of Chemotherapy or Radiotherapy and the Neurokinin-1 Receptor Antagonist Aprepitant: A New Antitumor Strategy?
Robinson P; Coveñas R; Muñoz M
Curr Med Chem; 2023; 30(16):1798-1812. PubMed ID: 35959620
[TBL] [Abstract][Full Text] [Related]
9. Neurokinin-1 Receptor Antagonists against Hepatoblastoma.
Muñoz M; Rosso M; Coveñas R
Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31466222
[TBL] [Abstract][Full Text] [Related]
10. The NK-1R Antagonist Aprepitant Prevents LPS-Induced Oxidative Stress and Inflammation in RAW264.7 Macrophages.
Zhao XN; Bai ZZ; Li CH; Sheng CL; Li HY
Drug Des Devel Ther; 2020; 14():1943-1952. PubMed ID: 32546961
[TBL] [Abstract][Full Text] [Related]
11. The NK-1 receptor antagonist L-732,138 induces apoptosis in human gastrointestinal cancer cell lines.
Muñoz M; Rosso M; Coveñas R
Pharmacol Rep; 2017 Aug; 69(4):696-701. PubMed ID: 28550801
[TBL] [Abstract][Full Text] [Related]
12. Advances in the research and application of neurokinin-1 receptor antagonists.
Hong X; Ma J; Zheng S; Zhao G; Fu C
J Zhejiang Univ Sci B; 2024 Feb; 25(2):91-105. PubMed ID: 38303494
[TBL] [Abstract][Full Text] [Related]
13. The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines.
Muñoz M; Rosso M; Robles-Frias MJ; Salinas-Martín MV; Rosso R; González-Ortega A; Coveñas R
Lab Invest; 2010 Aug; 90(8):1259-69. PubMed ID: 20458280
[TBL] [Abstract][Full Text] [Related]
14. The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines.
Muñoz M; González-Ortega A; Coveñas R
Invest New Drugs; 2012 Apr; 30(2):529-40. PubMed ID: 21120581
[TBL] [Abstract][Full Text] [Related]
15. Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists.
Molinos-Quintana A; Trujillo-Hacha P; Piruat JI; Bejarano-García JA; García-Guerrero E; Pérez-Simón JA; Muñoz M
Invest New Drugs; 2019 Feb; 37(1):17-26. PubMed ID: 29721755
[TBL] [Abstract][Full Text] [Related]
16. Aprepitant inhibits the development and metastasis of gallbladder cancer via ROS and MAPK activation.
Cao X; Yang Y; Zhou W; Wang Y; Wang X; Ge X; Wang F; Zhou F; Deng X; Miao L
BMC Cancer; 2023 May; 23(1):471. PubMed ID: 37221457
[TBL] [Abstract][Full Text] [Related]
17. Triple Negative Breast Cancer: How Neurokinin-1 Receptor Antagonists Could Be Used as a New Therapeutic Approach.
Muñoz M; Rosso M; Coveñas R
Mini Rev Med Chem; 2020; 20(5):408-417. PubMed ID: 31721701
[TBL] [Abstract][Full Text] [Related]
18. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug.
Muñoz M; Rosso M
Invest New Drugs; 2010 Apr; 28(2):187-93. PubMed ID: 19148578
[TBL] [Abstract][Full Text] [Related]
19. The Potential In Vitro Inhibitory Effects of Neurokinin-1 Receptor (NK-1R) Antagonist, Aprepitant, in Osteosarcoma Cell Migration and Metastasis.
Alsaeed MA; Ebrahimi S; Alalikhan A; Hashemi SF; Hashemy SI
Biomed Res Int; 2022; 2022():8082608. PubMed ID: 36177059
[TBL] [Abstract][Full Text] [Related]
20. The neurokinin-1 receptor antagonist aprepitant ameliorates oxidized LDL-induced endothelial dysfunction via KLF2.
Zheng J; Chen K; Zhu Y; Wang H; Chen Z; Yong X; Yin H; Chen J; Lai K; Liu Y
Mol Immunol; 2019 Feb; 106():29-35. PubMed ID: 30576949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
